MediGene Receives New US Patent for Cancer-Killing Viruses
Patent protects herpes simplex viruses (HSV) genetically modified to activate the immune system against tumor cells
16-Mar-2004 -
Martinsried - San Diego. The German-American biotechnology company MediGene AG (Frankfurt, Prime has received a patent for oncolytic (cancer-killing) viruses from the US Patent and Trademark Office. This patent protects a specific method of eliciting an immune response to tumor cells using ...
biotechnology
brain tumors
clinical trials
+8